Beta Bionics, Inc. · NASDAQ:BBNX
Beta Bionics — Investor Presentation (September 2026)
37 slides from Beta Bionics's investor presentation, Sep 15, 2026
Slide 1: Investor Presentation September 2026
Investor Presentation September 2026 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without lim
Slide 3: Disclaimer (Cont'd)
Disclaimer (Cont’d) This presentation contains trademarks, service marks, trade names and copyrights of the Company and other companies which are the property of their respective owners. This presentation discusses certain product candidates that have not yet received marketing authorization or clea
Slide 4: Our mission is to simplify and alleviate the burden of managing diabetes
Our mission is to simplify and alleviate the burden of managing diabetes with life-changing solutions.
Slide 5: Market-Leading Innovators
Market-Leading Innovators Beta Bionics has the only fully adaptive insulin-dosing algorithm, and most advanced system available in the U.S.1 Note:Data as of Q2 2026. Multiple Daily Injections (MDI). Year End (YE). Cook, K., et al. (2025). Defining the Automated Insulin Delivery Continuum: User Engag
Slide 6: Total $12B Addressable Market for Insulin Delivery in the U.S.
Total $12B Total Addressable Market for Insulin Delivery in the U.S. ~1.2M On multiple daily injections (MDI) >1.7M On multiple daily injections (MDI) >0.7M On pump therapy <0.2M On pump therapy 1.9M People in the U.S. 1.9M People in the U.S. Pump penetration ~39% Pump penetration <10% Type 1 Diabet
Slide 7: Poor Clinical Outcomes for People with T1D in the U.S.
~80% not at treatment goal, defined by the ADA as HbA1c <7% ~80% of people with T1D are not at ADA goal1,2 ~20% of people with T1D are at ADA goal, but many are overburdened with their diabetes management ~380K People with T1D Not meeting goal & overburdened ~1.5M People with T1D Meeting goal & over
Slide 8: Penetration remains low and treatment outcomes are poor
Penetration remains low and treatment outcomes are poor Source: Internal estimates informed by data from the CDC, Seagrove Partners, and publicly-reported 2025 product sales data. Note:Type 1 Diabetes (T1D). Type 2 Diabetes (T2D), American Diabetes Association (ADA). Foster et al. Diabetes Technol T
Slide 9: The Market Responds to Major Ease-of-Use Innovations
First FDA-approved CGM without calibration CGM and Pump Penetration in T1D 2013-2025 in the U.S. Source: Internal estimates informed by data from the CDC, Seagrove Partners, and publicly-reported 2025 product sales data. Note: Continuous Glucose Monitor (CGM), U.S. Food & Drug Administration (FDA),
Slide 10: We believe we can do more for people with diabetes.
We believe we can do more for people with diabetes.
Slide 11: Most Advanced Pump Platform in the U.S.
Most Advanced Pump Platform in the U.S.1 Adaptive-Closed Loop Algorithm Robust Digital Ecosystem Pharmacy Channel Access One Engine. A New Standard. iLet (Tubed Pump) Mint (Patch Pump) Note:Mint is not yet available for sale. Cook, K., et al. (2025). Defining the Automated Insulin Delivery Continuum
Slide 12: First and Only Fully Adaptive Closed-Loop Algorithm
Meal Announcement No Carb Counting User must be carb aware Beta Bionics Adaptive Closed-Loop Algorithms Algorithm learns and adapts to the user’s insulin requirements Initialized with only the user’s body weight User only announces meals; no carb counting* No adjustment of settings by the provider r
Slide 13: 3D Intelligence, Beta Bionics' Next-Gen Algorithm
*Minor differences in adaptation compared to previous algorithm are not anticipated to have a significant impact on outcomes. Note:Commercialization of iLet 3D and Mint 3D is subject to regulatory clearance of 3D Intelligence by the FDA, and the devices are not available for sale. Actual product fea
Slide 14: iLet Bionic Pancreas
iLet Bionic Pancreas Sleek tubed pump design with control screen on pump and option to use pre-filled Fiasp PumpCart Abbott’s FreeStyle Libre 3 Plus Sensor Dexcom G7 & G7 15 Day Dexcom G6 Smartphone Insulin Cartridge Infusion Set
Slide 15: Mint Patch Pump
Note: The images shown are for illustrative purposes only. Actual product specifications may vary. Mint is not yet available for sale. Continuous glucose monitor (CGM). Mint Patch Pump FDA Cleared in September 2026; Full Commercial Launch in the U.S. expected in Q1 2027 New, innovative reusable-disp
Slide 16: Potential Business Advantages
Potential Business Advantages Expands Addressable Market Reimbursed Exclusively in the Pharmacy Channel Cost Effective to Manufacture at Scale Limits Environmental Waste R x Targeting Mint Full U.S. Commercialization in Q1 2027 Note: Mint is not yet available for sale.
Slide 17: Providing Flexible Reimbursement
Note:The information presented on this slide is for illustrative purposes only and expresses estimated dollar amounts. Durable Medical Equipment (DME). DME (Medical) Pharmacy Traditional reimbursement channel for durable insulin pumps Pay-as-you-go model with advantages for users, providers, payors,
Slide 18: Pharmacy Channel Strategy
Pharmacy Channel Strategy Streamlined insurance approval Users Providers Payers Beta Bionics Less administrative burden Lower out-of-pocket costs Higher Customer Lifetime Value No 4-year pump commitment Faster Access to New Users Pay-as-you-go economics PBM Agreement 1 Health Plan Adoption 2 Time &
Slide 19: Robust Digital Ecosystem
Robust Digital Ecosystem For our users, their caregivers, and their healthcare providers iLet and Mint Apps (iOS & Android) Easy-to-use interface Automatic data uploads to the cloud Bionic Circle App (iOS & Android) Remote monitoring experience for family members, friends, and caregivers Bionic Port
Slide 20: Positioning for success
Beta Bionics Positioning for success
Slide 21: Competitive comparison of algorithms, form factor, CGM integration and reimbursement
Fully Adaptive Algorithm Tubeless Hybrid Closed-loop System Tubed Hybrid Closed-loop System Smart Insulin Pens Insulet2 MiniMed and Tandem3,4 Multiple Algorithm(s) Algorithm(s) initialized with only body weight ü × × × Algorithm(s) determines 100% of insulin doses ü × × × No carb counting5 ü × × × F
Slide 22: HbA1c improvement with iLet vs. standard of care
- 0.6 - 0.0 - 0.7 - 0.1 - 0.6 - 0.0 - 0.9 - 0.1 - 1.0 - 0.0 - 0.5 - 0.0 - 0.3 - 0.1 HbA1c % Improvement with iLet1 HbA1c % Improvement with SoC1 All Users Adults Children At least 7% Baseline HbA1c Multiple Daily Injections (MDI) Pumps Hybrid Closed-Loop2 iLet delivered greater reduction in HbA1c vs
Slide 23: Real-world HbA1c change by baseline HbA1c
Baseline HbA1c Group Average Baseline HbA1c Average Change Average GMI on the iLet 15.0% 13.7% 12.5% 11.5% 10.5% 9.5% 8.9% 8.5% 7.6% 6.6% 5.7% 14-19% 13-14% 12-13% 11-12% 10-11% 9-10% 8-9% Overall 7-8% 6-7% 4-6% (N=215) (N=457) (N=533) (N=895) (N=1,388) (N=2,238) (N=14,952) (N=3,095) (N=3,615) (N=2,
Slide 24: Severe hypoglycemia event rates
SH1 Event(s) per 100 Patient Years Note: Severe Hypoglycemia (SH) defined as hypoglycemia with cognitive impairment requiring the assistance of a third party for treatment. Automated Insulin Delivery (AID). Data presented are not based on head-to-head studies. As a result, cross-study comparisons ca
Slide 25: Time to Steady-State GMI
Time to Steady-State GMI (N=30,077 sessions1) Average baseline HbA1c of 8.9% to follow-up GMI on iLet of 7.4% just 2 days after initiation Baseline HbA1c (%) Source:The real-world data presented are observational data. These data do not come from a prospective study designed to assess safety and eff
Slide 26: Results by provider practice type
-1.6 Baseline HbA1c to Follow-Up GMI Practice Type: Endocrinology Practice Type: Primary Care -1.6 Similar improvement in GMI with >84% of users meeting ADA hypoglycemia goals, regardless of provider practice type N=13,566 N=1,036 Source:The real-world data presented is observational data. These dat
Slide 27: Real-world Data: Change by Level of Engagement
iLet Real-world Data: Change from Baseline HbA1c to Mean GMI by Level of Engagement in Adults (≥ 18 years old) Source:The real-world data presented is observational data. These data do not come from a prospective study designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by basel
Slide 28: Fully-closed loop use of iLet
-1.9 Baseline HbA1c to Follow-Up GMI ~16% of iLet users (with available data) use the pump in a “fully-closed loop” manner1 On average, “fully-closed loop” iLet users announced ~1 meal every 3 days “Fully-closed loop” users achieved ~62% time in range, on average ~83% of “fully-closed loop” iLet use
Slide 29: Where we are going next
Beta Bionics Where we are going next
Slide 30: Build On iLet's Highly Successful Commercial Launch
~69% New patient starts coming from multiple daily injections in Q2’26 High 30s % New patient starts reimbursed through pharmacy in Q2’26 Gross Margin ($ in millions) Build On iLet’s Highly Successful Commercial Launch Launched in May 2023, iLet is expanding the pump market and taking market share R
Slide 31: Beta Bionics Innovation Pipeline
Next-Gen Algorithm: 3D Intelligence Type 2 Diabetes (T2D) Indication Expansion Fully-Closed Loop (FCL) Algorithm Bihormonal System Note: U.S. Food & Drug Administration (FDA). Investigational Device Exemption (IDE), New Drug Application (NDA). Subject to regulatory clearance The Company estimates th
Slide 32: Type 2 Diabetes Primary Care Opportunity
Of the 1.9M people with T1D in the U.S. are treated by PCPs ~50% Of people with T2D in the U.S. are treated by PCPs ~90% Pump penetration in primary care in the U.S. <10% 1.9M People with T2D in the U.S. who require intensive insulin (IIT) Pump penetration in T2D IIT population in the U.S. <10% <0.2
Slide 33: Bihormonal System
First-of-its-kind bihormonal configuration of the iLet Intended to utilize adaptive closed-loop algorithms that autonomously determine and deliver 100% of all insulin and glucagon doses Exclusive collaboration and license agreement with Xeris Pharmaceuticals for a pump-compatible, shelf-stable, gluc
Slide 34: Full Year 2026 Guidance
Anticipated revenue deferral of up to $10 million in Q4 2026 as new prospective iLet users await the launch of Mint Stable utilization and retention across DME and pharmacy channels Contribution from at least 20 new sales territories onboarded in the first half of 2026 Execution of additional formul
Slide 35: Strategic Outlook: Innovating for today and the future
Innovating for today and the future Strategic Outlook iLet launch (Black & White) CGM integrations (Dexcom G6 & G7, Abbott Freestyle Libre 3 Plus) Formulary agreements (e.g., Express Scripts & CVS Caremark) Collaboration and licensing agreement with Xeris Pharmaceuticals Color iLet launch Expansion
Slide 36: Appendix
Beta Bionics Appendix
Slide 37: Quarterly Financials & Reconciliation to GAAP Financials
Adjusted EBITDA addbacks include stock-based compensation expense, depreciation and amortization expense, interest income, provision for state taxes, litigation settlement expense, quality system remediation, and change in fair value of warrant liabilities. Amounts presented under “Quality system re
Beta Bionics — Investor Presentation (September 2026) on 6ix